Cerebricon Ltd. Opens Business Offices in USA and UK
19 December 2005
Dec 12, 2005 Kuopio, Finland; London, UK
Cerebricon Ltd. Announces Launch of UK and USA Sales Offices
In order to enhance its ability to maintain communications with current and prospective customers, in the USA and in Europe. Cerebricon has opened two Sales, Marketing and Business Development Offices. The opening of these offices will allow better access and better communication with current and prospect clients and collaborators.
Dr Juha Yrjanheikki, Cerebricon's CEO said, "This is a good opportunity for us to get closer to our drug development clients and collaborators in these areas. Our headquarters will still be based in Kuopio, Finland but we welcome this as an opportunity to provide an easier method of contact for our customers."
Please see the 'regional offices' page of our profile for contact details for the new offices.
